Provided by Tiger Trade Technology Pte. Ltd.

I-MAB

4.63
0.0000
Volume:- -
Turnover:7.03M
Market Cap:533.68M
PE:-9.44
High:4.63
Open:4.63
Low:4.63
Close:4.63
52wk High:6.79
52wk Low:0.5950
Shares:115.27M
Float Shares:48.23M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4902
EPS(LYR):-0.2738
ROE:-18.46%
ROA:-10.36%
PB:2.71
PE(LYR):-16.91

Loading ...

I-Mab Files for Dual Primary Listing on Hong Kong Stock Exchange

Reuters
·
Oct 31, 2025

BRIEF-I-Mab Transitions To NovaBridge Biosciences With Trading Effective October 30, 2025

Reuters
·
Oct 29, 2025

I-Mab (Nasdaq: Imab) Transitions to Novabridge Biosciences (Nasdaq: Nbp) With Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

THOMSON REUTERS
·
Oct 29, 2025

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

GlobeNewswire
·
Oct 29, 2025

BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)

TIPRANKS
·
Oct 24, 2025

I-Mab Issues Amendment to October 2025 SEC Filing

Reuters
·
Oct 24, 2025

I-Mab Price Target Maintained With a $9.00/Share by BTIG

Dow Jones
·
Oct 24, 2025

I-MAB Reports Positive Phase I Results for Givastomig in Gastroesophageal Cancer

TIPRANKS
·
Oct 24, 2025

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

GlobeNewswire
·
Oct 23, 2025

I-Mab Is Maintained at Buy by BTIG

Dow Jones
·
Oct 18, 2025

I-Mab to Rebrand as NovaBridge Biosciences, Eyes Hong Kong IPO

MT Newswires Live
·
Oct 17, 2025

I-Mab - Kyler Lei Appointed as CFO of I-Mab

THOMSON REUTERS
·
Oct 17, 2025

Press Release: I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

Dow Jones
·
Oct 17, 2025

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

GlobeNewswire
·
Oct 14, 2025

BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)

TIPRANKS
·
Oct 14, 2025

Leerink Partners Initiates Coverage on I-MAB With Outperform Rating, $9 Price Target

MT Newswires Live
·
Oct 03, 2025

I-Mab Initiated at Outperform by Leerink Partners

Dow Jones
·
Oct 03, 2025

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), I-MAB (IMAB) and Cidara Therapeutics (CDTX)

TIPRANKS
·
Oct 03, 2025

I-Mab initiated with an Outperform at Leerink

TIPRANKS
·
Oct 03, 2025

BUZZ-I-Mab tumbles on China drug report, analyst calls selloff overreaction

Reuters
·
Sep 11, 2025